一名接受芦可替尼治疗的原发性骨髓纤维化的新冠病毒阳性老年女性对聚乙二醇化干扰素的反应。
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.
作者信息
Frankel Arthur E, Reddy Renuka, DeSuza Kayla R, Deeb Khaled, Carlin Aaron F, Smith Davey, Xie Yushuang, Naik Eknath, Silver Richard T, Hasselbalch Hans C
机构信息
Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
Division of Infectious Disease UCSD Medical School San Diego CA USA.
出版信息
Clin Case Rep. 2021 Mar 7;9(4):2228-2235. doi: 10.1002/ccr3.3997. eCollection 2021 Apr.
Abstract
An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.
摘要
一名83岁女性在服用鲁索替尼期间感染了无症状的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。她的病毒核糖核酸（RNA）逆转录聚合酶链反应（RT-PCR）检测持续阳性超过120天，聚乙二醇化干扰素治疗4周后病毒RNA清除。这些观察结果支持鲁索替尼联合干扰素治疗2019冠状病毒病（COVID-19）。
相似文献
1
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.一名接受芦可替尼治疗的原发性骨髓纤维化的新冠病毒阳性老年女性对聚乙二醇化干扰素的反应。
Clin Case Rep. 2021 Mar 7;9(4):2228-2235. doi: 10.1002/ccr3.3997. eCollection 2021 Apr.
2
Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.芦可替尼治疗的原发性骨髓纤维化患者尽管合并症严重，但 COVID-19 病情良好。
Eur J Haematol. 2020 Nov;105(5):655-658. doi: 10.1111/ejh.13480. Epub 2020 Jul 16.
3
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.mRNA SARS-CoV-2 疫苗的第三剂加强了骨髓纤维化患者的刺突特异性抗体和记忆 B 细胞反应。
Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022.
4
Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.接受羟基脲、聚乙二醇化干扰素α-2A或鲁索替尼治疗的骨髓增殖性肿瘤：真实世界中的临床血液学反应、生活质量变化及安全性
Hematology. 2020 Dec;25(1):247-257. doi: 10.1080/16078454.2020.1780755.
5
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.COVID-19 作为干扰素缺乏和炎症过度活跃的中介：联合使用 JAK1/2 抑制剂与干扰素的原理。
Cytokine Growth Factor Rev. 2021 Aug;60:28-45. doi: 10.1016/j.cytogfr.2021.03.006. Epub 2021 Apr 14.
6
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.干扰素-α2 与芦可替尼联合治疗真性红细胞增多症和骨髓纤维化的安全性和有效性。
Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.
7
A Case of Primary Myelofibrosis in Which Ruxolitinib Therapy Ameliorated the Fibrosis, but Resulted in Fatty Marrow.一例原发性骨髓纤维化病例，鲁索替尼治疗改善了纤维化，但导致了骨髓脂肪化。
Gan To Kagaku Ryoho. 2020 Feb;47(2):279-285.
8
[Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis].[真性红细胞增多症后骨髓纤维化转化的急性髓系白血病患者在异基因造血干细胞移植前使用鲁索替尼成功治疗脾肿大]
Rinsho Ketsueki. 2017;58(7):743-748. doi: 10.11406/rinketsu.58.743.
9
Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.对未接受机械通气的新型冠状病毒肺炎患者同情用药鲁索替尼：对炎症和通气的短期影响
Clin Transl Sci. 2021 May;14(3):1062-1068. doi: 10.1111/cts.12971. Epub 2021 Jan 27.
10
[Fatal primary influenza virus pneumonia in a patient with secondary myelofibrosis during ruxolitinib therapy].[芦可替尼治疗期间继发骨髓纤维化患者发生致命性原发性流感病毒肺炎]
Rinsho Ketsueki. 2022;63(2):108-110. doi: 10.11406/rinketsu.63.108.
引用本文的文献
1
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19.几种治疗新型冠状病毒肺炎的药物疗效综述
Life (Basel). 2022 Nov 1;12(11):1758. doi: 10.3390/life12111758.
2
Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.当前干扰素 α 在治疗 2019 冠状病毒病中的应用：全面综述。
Cytokine Growth Factor Rev. 2022 Feb;63:34-43. doi: 10.1016/j.cytogfr.2022.01.001. Epub 2022 Jan 13.
3
The role of type I interferon in the treatment of COVID-19.I 型干扰素在 COVID-19 治疗中的作用。
J Med Virol. 2022 Jan;94(1):63-81. doi: 10.1002/jmv.27317. Epub 2021 Sep 17.
4
Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.接受依维莫司治疗的转移性空肠神经内分泌肿瘤新冠阳性男性患者对聚乙二醇化干扰素的反应
Clin Case Rep. 2021 Jun 9;9(6):e04218. doi: 10.1002/ccr3.4218. eCollection 2021 Jun.
5
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.COVID-19 作为干扰素缺乏和炎症过度活跃的中介：联合使用 JAK1/2 抑制剂与干扰素的原理。
Cytokine Growth Factor Rev. 2021 Aug;60:28-45. doi: 10.1016/j.cytogfr.2021.03.006. Epub 2021 Apr 14.
本文引用的文献
1
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.SARS-CoV-2、SARS-CoV 和 MERS-CoV 的病毒载量动态、病毒脱落持续时间和传染性：系统评价和荟萃分析。
Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.
2
Genetic mechanisms of critical illness in COVID-19.新型冠状病毒肺炎危重症的遗传机制。
Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
3
Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.用于类固醇难治性急性移植物抗宿主病的实验性药物
J Exp Pharmacol. 2020 Nov 26;12:549-557. doi: 10.2147/JEP.S259290. eCollection 2020.
4
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.巴黎地区 SARS-CoV-2 感染的高血清阳性率但短暂的免疫应答。
Eur J Immunol. 2021 Jan;51(1):180-190. doi: 10.1002/eji.202049058. Epub 2020 Dec 23.
5
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.病例研究：一名患有癌症的无症状免疫功能低下个体长期感染性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）脱落。
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.
6
Inference of Active Viral Replication in Cases with Sustained Positive Reverse Transcription-PCR Results for SARS-CoV-2.在 SARS-CoV-2 持续阳性逆转录聚合酶链反应结果的病例中推断病毒的活跃复制。
J Clin Microbiol. 2021 Jan 21;59(2). doi: 10.1128/JCM.02277-20.
7
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.芦可替尼与干扰素-α2 联合治疗真性红细胞增多症或骨髓纤维化患者：一项 II 期研究。
Haematologica. 2020 Sep 1;105(9):2262-2272. doi: 10.3324/haematol.2019.235648.
8
Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）感染持续时间：何时可以安全解除隔离？
Clin Infect Dis. 2021 Apr 26;72(8):1467-1474. doi: 10.1093/cid/ciaa1249.
9
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19.一项关于IFN-κ联合TFF2与标准治疗方案治疗中度COVID-19患者的开放标签随机试验。
EClinicalMedicine. 2020 Oct;27:100547. doi: 10.1016/j.eclinm.2020.100547. Epub 2020 Sep 20.
10
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
Zotero 插件